Prostatype Genomics receives commitments and letters of intent of approx. 70 percent of the exercise of warrants TO6

Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has, ahead of the upcoming exercise of warrants of series TO6 ("TO6"), entered into a top-down underwriting agreement with Vator Securities AB ("Vator Securities") corresponding to SEK 6.0 million (48 percent), and has received subscription commitments and letters of intent corresponding to a total of approximately SEK 2.7 million (22 percent). In total, the subscription commitments, letters of intent and top-down underwriting commitment correspond to approximately SEK 8.7 million, equivalent to approximately 70 percent of the approximately SEK 12.5 million that TO6 may provide the Company with at maximum, before deduction of issue costs. The underwriting commitment will become effective if not all TO6 are exercised by the warrant holders. The exercise period for TO6 commences on 1 September 2026 and runs until and including 15 September 2026. The last day of trading in TO6 is 11 September 2026.

In July 2026, Prostatype Genomics carried out a rights issue that provided the Company with approximately SEK 47.4 million before deduction of issue costs. Through the rights issue and a directed share issue, 125,225,546 TO6 were issued.

Each TO6 entitles the holder to subscribe for one (1) new share in Prostatype Genomics during the exercise period from 1–15 September 2026. The exercise price for TO6 is SEK 0.10 per share. Upon full exercise of TO6, the Company will receive approximately SEK 12.5 million before deduction of issue costs.

Upon full exercise of TO6, the number of shares in Prostatype Genomics will increase by 125,225,546 shares to a total of 685,317,051 shares, and the share capital will increase by SEK 12,522,554.60 to SEK 68,531,705.10. The dilution upon full exercise amounts to approximately 18.3 percent of the share capital and votes.

The complete terms and conditions and instructions for TO6 are available on the Company's website (www.prostatypegenomics.com). A teaser containing summary information about TO6 will be available on Prostatype Genomics' website (www.prostatypegenomics.com) no later than when the exercise period commences.

Subscription commitments, letters of intent and top-down underwriting commitment
Ahead of the exercise of TO6, the Company has entered into an agreement regarding a top-down underwriting commitment with Vator Securities corresponding to approximately 48 percent (SEK 6.0 million) of TO6. The underwriter will receive a fee of 2 percent in cash and 10 percent in shares, on the same terms and conditions as TO6. Vator Securities has the requisite authorization to act as an issue underwriter and has entered into separate option agreements with a number of investors regarding the transfer of any shares allocated upon any fulfilment of the aforementioned underwriting commitment.

In addition, the Company has received subscription commitments corresponding to approximately 4 percent (SEK 0.46 million), as well as letters of intent from the Board of Directors, management and a number of other warrant holders, corresponding to approximately 18 percent (SEK 2.27 million).

The commitments are not secured by bank guarantees, pledges or similar arrangements. The top-down underwriting commitment will be activated if subscriptions for shares through the exercise of TO6 amount to less than 100 percent. Subscription under the underwriting commitment will be made through a directed share issue, resolved upon by the Board of Directors pursuant to the authorization granted by the Annual General Meeting held on 22 June 2026.

Advisors
Navia Corporate Finance AB and Birchtree Advisory AB are financial advisors in connection with the warrant exercise. Advokatfirman Lindahl is the legal advisor. Vator Securities AB is the issuing agent.

For more information about the warrant exercise, please contact:
Navia Corporate Finance AB
E-mail: info@naviacf.se
Website: www.naviacorporatefinance.com

or

Birchtree Advisory AB
E-mail: jonas.bjorkman@birchtreeadvisory.se
Website: www.birchtreeadvisory.se

For more information about the Company, please contact:
Fredrik Rickman, CEO Prostatype Genomics AB
Phone: +46 (0)73 049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com

Certified Adviser
Tapper Partners AB
Phone: +46 (0)70 44 010 98
E-mail: ca@tapperpartners.se

About Prostatype Genomics
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, or other securities in Prostatype Genomics. No action has been taken, and no action will be taken, to permit an offer to the public in any jurisdiction other than Sweden. The invitation to interested persons to subscribe for shares in Prostatype Genomics has only been made through the information memorandum published by the Company on its website.

The information in this press release may not be released, published, or distributed, directly or indirectly, in or into the United States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction where such action would be unlawful, subject to legal restrictions, or require measures other than those required under Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in Prostatype Genomics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, sold, or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction in the United States. This press release is distributed and directed only to persons in the United Kingdom who are (i) investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) high net worth entities and other persons to whom this press release may lawfully be communicated, falling within Article 49(2)(a)-(d) of the Order (all such persons together being referred to as "Relevant Persons"). Persons who are not Relevant Persons must not act on or rely on the information contained in this press release. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will only be engaged in with Relevant Persons. Persons distributing this communication must satisfy themselves that such distribution is lawful.

Forward-looking statements
This press release contains forward-looking statements concerning the Company's intentions, assessments, or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies, and opportunities, as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and may be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "assumes," "should," "could," and, in each case, their negative forms, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are in turn based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are

reasonable, there can be no assurance that they will materialize or prove to be correct. Because these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes may differ materially from those expressed in the forward-looking statements for a variety of reasons.

Such risks, uncertainties, unforeseen events, and other significant factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are correct, and readers of this press release should not place undue reliance on the forward-looking statements contained herein. The information, opinions, and forward-looking statements expressed or implied in this press release speak only as of the date of this press release and are subject to change. Neither the Company nor any other party undertakes to review, update, confirm, or publicly announce any revision to any forward-looking statement to reflect events that occur or circumstances that arise in relation to the contents of this press release, except as required by law or the Nasdaq First North Growth Market Rulebook for Issuers.

This information is information that Prostatype Genomics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-08-31 10:40 CEST.